Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Assets: 2021-2024

Historic Other Non-Current Assets for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $3.1 million.

  • ARS Pharmaceuticals' Other Non-Current Assets rose 674.01% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 674.01%. This contributed to the annual value of $3.1 million for FY2024, which is 388.09% up from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Other Non-Current Assets is $3.1 million, which was up 388.09% from $638,000 recorded in FY2023.
  • ARS Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $3.1 million during FY2024, with a 5-year trough of $23,000 in FY2021.
  • Its 3-year average for Other Non-Current Assets is $2.2 million, with a median of $3.0 million in 2022.
  • Per our database at Business Quant, ARS Pharmaceuticals' Other Non-Current Assets soared by 12,773.91% in 2022 and then slumped by 78.45% in 2023.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Other Non-Current Assets stood at $23,000 in 2021, then spiked by 12,773.91% to $3.0 million in 2022, then plummeted by 78.45% to $638,000 in 2023, then soared by 388.09% to $3.1 million in 2024.